Instructions for presentations

Technical requirements



- POSTER PRESENTATION:

Recommended Poster Size: 90x120cm (Portrait)


- POWERPOINT PRESENTATION:


Compulsory format for PowerPoint presentations in the moderated poster sessions:

  • * Every slide (all 6 in every presentation) must be clearly labeled with the abstract/poster number in the top left corner. This number can be found in the “List of accepted publications” below.
  • * The presentation is limited to max. 6 slides with no animations, sequential build-up of individual slides or videos.
  • * Slide 1 should contain the abstract title, list of authors and affiliations only.
  • * Slide 2-5 should contain a brief introduction and clearly stated hypothesis if deemed necessary, as well as results from the abstract and poster, preferably as figures and/or tables.
  • * Slide 6 should contain summary and/or conclusion(s) in bullet points.

Technical requirements:

  • * Microsoft PowerPoint 2010 on a Windows 7 based PC will be used for all presentations.
  • * Slides must be fitted to be used on a laptop with screen resolution around 1280 x 800 pixels.
  • * Use the “Insert” feature of PowerPoint to add images to your presentations. Do not copy/paste images into the slide or click and drag.
  • * Ensure no video or animation is included in the presentation.
  • * Please note that Internet access will not be available.
  • * No sound system will be connected to the computer.
  • * "Presenter view" is turned off in PowerPoint
  • * Maximum file size 50Mbyte.

The following file types are the only acceptable:

  • * Microsoft Office PowerPoint Presentation (.pptx)
  • * Microsoft Office PowerPoint 97-2003 Presentation (.ppt)



- INSTRUCTIONS FOR SUBMITTING PRESENTATIONS
Please enter Poster number when submitting your presentation.


- LIST OF ACCEPTED PRESENTATIONS, CHFR- 2017
Poster number and Name

Session I Biomarkers and Cardiac Disease
I-1 Shetelig C
I-2 Kalstad AK
I-3 Opstad, TB
I-4 Tveit, S. H.
I-5 Bogsrud MP
I-6 Auensen A., Associations of brain–natriuretic peptide...
I-7 Bogdanova M
I-8 Skranes JB
I-9 Robinson E L
I-10 Erika Nerdrum Aagaard
I-11 Myhre, P. L.
I-12 Arseny Zabirnyk

Session II Cellular Signaling: Myocardial Hypertrophy and Ischemia
II-1 Melleby AO
II-2 Olsen MB
II-3 Lipsett DB
II-4 Romaine A
II-5 Mathiesen SB
II-6 Christina Mathisen Heiestad
II-7 Ana I. Calejo
II-8 Kaasboll OJ
II-9 Maria Vistnes
II-10 Andenas K
II-11 Mohammadzadeh N
II-12 Zolfaghari S
II-13 Lothe GB

Session III Cardiac Function During Heart Failure and Exercise Training
III-1 Ljones K
III-2 LA Dejgaard
III-3 Rolid K
III-4 Wohlwend M
III-5 Cwikiel J
III-6 Kleiven Ø
III-7 Aalen J
III-8 Larsen CK
III-9 Storsten P
III-10 McGinley, G.
III-11 Espe E

Session IV Cellular Signaling: Myocardial Function and Arrhythmias

IV-1 J. Li
IV-2 V. Timmermann
IV-3 Brink J. v. d.
IV-4 Shen X
IV-5 Terje R. Kolstad
IV-6 Manfra O
IV-7 C. Le
IV-8 Albert I
IV-9 Cosson MV
IV-10 Frisk M
IV-11 Ruud M
IV-12 Gaia Calamera
IV-13 P. Wanichawan

Session V Diagnostic and Therapeutical Strategies for Cardiac Disease
V-1 Ofstad AP
V-2 Witczak BN
V-3 Andresen, H
V-4 Bergo KK
V-5 Brede Kvisvik
V-6 Lie OH
V-7 Andersen OS
V-8 Bendiksen BA
V-9 Rodland L
V-10 Auensen A - Morbidity outcomes after surgical aortic valve replacement...
V-11 S.Fossum
V-12 Eskerud I

Session VI Inflammatory Mediators and Metabolism
VI-1 Langseth, M.S
VI-2 Yang K
VI-3 Orrem HL
VI-4 Marina Sokolova
VI-5 Akra S
VI-6 Udjus C
VI-7 Shahini N
VI-8 Anstensrud AK
VI-9 A Awoyemi
VI-10 Jansen K. M.
VI-11 Marstein H
VI-12 Jacob J. Christensen
VI-13 Torp, M-K

Webmaster Vidar, IEMF